The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?

Publisher： Karger

E-ISSN： 1423-0399|96|1|46-50

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.96, Iss.1, 2016-0, pp. : 46-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Contemporary cost‐effectiveness analysis comparing sequential bacillus Calmette‐Guerin and electromotive mitomycin versus bacillus Calmette‐Guerin alone for patients with high‐risk non–muscle‐invasive bladder cancer

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2424-2431

John Wiley & Sons Inc

Access to resources Recommend Favorite

Non‐muscle invasive bladder cancer and bacillus Calmette‐Guerin treatment: a review of the literature

By  

INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, Vol. 9, Iss. 2, 2015-07 ,pp. : 57-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intravesical Bacillus Calmette-Guerin Therapy for Grade 3 Non-Muscle Invasive Bladder Cancer: Results of Six or Eight Successive Instillations

By  

Current Urology, Vol. 5, Iss. 1, 2011-03 ,pp. : 41-45

Karger

Access to resources Recommend Favorite

The effectiveness of BCG and interferon against non‐muscle invasive bladder cancer: a New Zealand perspective

By  

BJU INTERNATIONAL, Vol. 116, Iss. S3, 2015-10 ,pp. : 54-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high‐risk non‐muscle‐invasive bladder cancer treated with maintenance intravesical Bacillus Calmette‐Guérin

By  

BJU INTERNATIONAL, Vol. 116, Iss. 5, 2015-11 ,pp. : 721-726

John Wiley & Sons Inc

Access to resources Recommend Favorite